EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY-NC-ND 4.0

Proteomic Profile After Intervention With Eplerenone Among Persons With HIV

Anirudh Murthy, Márton Kolossváry, Allie R Walpert iD, Eva Sanchez, Shady Abohashem iD, Ahmed Tawakol iD, Gail K Adler iD, Steven K Grinspoon, Suman Srinivasa iD

Open Forum Infectious Diseases · 30.03.2026 · 13 (4)

DOI: 10.1093/ofid/ofag207 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 08.04.2026. Verfasst von Anirudh Murthy und 8 weiteren Autor:innen. Beteiligte Einrichtung: Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, NIDDK NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Persons with human immunodeficiency virus (HIV) well-treated on antiretrovirals have increased arterial inflammation, which can lead to development of atherosclerotic disease. We have previously shown that treatment with eplerenone can significantly reduce arterial inflammation, as measured by target-to-background ratio (TBR) on cardiac 18F-fluorodeoxyglucose positron emission tomography/computed tomography, among people with HIV. The mechanisms by which eplerenone may have treatment effects remain unclear.

Methods

We performed a targeted discovery-based approach to identify a proteomics signature associated with eplerenone treatment that may provide a plausible mechanism for the reduction in arterial inflammation. In an exploratory study, we leveraged analyzable samples from participants who completed the 12-month, placebo-controlled, randomized controlled trial MIRABELLA HIV to evaluate 276 proteins (Olink Target 96 Cardiometabolic, Cardiovascular II, Cardiovascular III), with relevance to cardiovascular and cardiometabolic disease.

Results

We identified 11 proteins that differed in expression between treatment groups. Eight proteins (CDH1, CES1, ADM, IL-4RA, FGF-21, FS, FABP2, Gal-4) decreased and 2 proteins increased (CSTB, MPO) in expression with eplerenone compared to placebo. An increase in expression of IL-27 was prevented among eplerenone-treated versus placebo-treated groups. Changes in TBR of the most diseased segment of the index vessel correlated with changes in 3 of these proteins: CDH1 (ρ = 0.53, P = .02), FGF-21 (ρ = 0.64, P = .003), and Gal-4 (ρ = 0.58, P = .009).

Conclusions

Through this proteomics approach, we discovered that 3 key proteins, CDH1, FGF-21, and Gal-4, are decreased in parallel with reductions in arterial inflammation after treatment with eplerenone. Eplerenone-induced reductions in these proteins, known to be related to inflammation, epithelial barrier disruption, vascular dysfunction, and metabolic dysregulation, provide mechanistic insight into pathways by which eplerenone may improve cardiovascular disease in HIV. Clinical Trials Registration NCT02740179.

Schlagwörter

Stichwörter der Autor:innen

CDH1HIVarterial inflammationeplerenoneproteomics

Autor:innen und Institutionen

  • Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Education and Research, Gottsegen National Cardiovascular Center, Budapest, Hungary.
  • Physiological Controls Research Center, University Research and Innovation Center, Óbuda University, Budapest, Hungary.
  • Cardiovascular Imaging Research Center and Division of Cardiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Allie R Walpert, Shady Abohashem, Ahmed Tawakol, Gail K Adler, Suman Srinivasa

Förderung

  • NHLBI NIH HHS
  • NIDDK NIH HHS
  • National Institutes of Health

Zitieren

APA

Murthy, A., Kolossváry, M., Walpert, A. R., Sanchez, E., Abohashem, S., Tawakol, A., Adler, G. K., Grinspoon, S. K., & Srinivasa, S. (2026). Proteomic Profile After Intervention With Eplerenone Among Persons With HIV. Open Forum Infectious Diseases, 13(4). https://doi.org/10.1093/ofid/ofag207

Vancouver

Murthy A, Kolossváry M, Walpert AR, Sanchez E, Abohashem S, Tawakol A, et al. Proteomic Profile After Intervention With Eplerenone Among Persons With HIV. Open Forum Infectious Diseases. 2026;13(4). doi:10.1093/ofid/ofag207

BibTeX
@article{Murthy2026,
  author = {Murthy, Anirudh and Kolossváry, Márton and Walpert, Allie R and Sanchez, Eva and Abohashem, Shady and Tawakol, Ahmed and Adler, Gail K and Grinspoon, Steven K and Srinivasa, Suman},
  title = {Proteomic Profile After Intervention With Eplerenone Among Persons With HIV},
  journal = {Open Forum Infectious Diseases},
  year = {2026},
  volume = {13},
  number = {4},
  doi = {10.1093/ofid/ofag207}
}
Kostenlos starten →